DIAMOND
21 Dec 2020
DIAMOND
ACTRN12617001325392
BCT 1703 (DIAmOND): Patients with HER2-positive breast cancer that have progressed on prior trastuzumab therapy will be treated with a combination of tremelimumab and durvalumab, in combination with trastuzumab, to evaluate the efficacy of the combination
–
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2018-11-01 |
Anticipated End Date | 2020-11-01 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alex Scott-Hoy |
alex.scott-hoy@sa.gov.au | |
Phone | 08 8204 4830 |
Principal Investigator | Dr Sina Vatandoust |
Recruitment Status | Recruiting |